NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.13, pp.1219-1231, 2020 (SCI-Expanded, Scopus)
Background Patients with transfusion-dependent beta-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor beta superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.